MitchellBrinMDFAAN, FAHS, FANA(He/Him)

PubMed

• Reduction of masseter muscle prominence after treatment with onabotulinumtoxinA: Primary results from a randomized phase 2 study.
  Jean Carruthers, Steven Liew, Jason K Rivers, Shyi-Gen Chen, Shannon Humphrey
  Journal of the American Academy of Dermatology. 2024-11-09
• Versatility of OnabotulinumtoxinA in Aesthetic Medicine.
  Mitchell F Brin, John Maltman, Mary Ann Chapman, Sara Sangha
  Dermatologic Surgery. 2024-09-01
• Exploring the effects of extracranial injections of botulinum toxin type A on activation and sensitization of central trigeminovascular neurons by cortical spreading d...
  Agustin Melo-Carrillo, Andrew M Strassman, Khrystoffer-Kihan J Malcolm, Aubrey Manack Adams, Brett Dabruzzo
  Cephalalgia. 2024-09-01

Journal Articles

• Botulinum neurotoxin type A-cleaved SNAP25 is confined to primary motor neurons and localized on the plasma membrane following intramuscular toxin injection  
  Cai BB, Francis J, Brin MF, Broide RS, Neuroscience, 1/1/2017
• Repeated onabotulinumtoxinA treatment of glabellar lines at rest over three treatment cycles  
  Carruthers A, Carruthers J, Fagien S, Lei X, Kolodziejczyk J, Brin MF, Dermatol.Surg., 1/1/2016
• Impact of cervical dystonia on work productivity: an analysis from a patient registry  
  Molho ES, Stacy M, Gillard P, Charles D, Adler CH, Jankovic J, Schwartz M, Brin MF, Mov Disord.Clin.Pract., 1/1/2016
• Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE)  
  Jankovic J, Adler CH, Charles D, Comella C, Stacy M, Schwartz M, Manack AA, Brin MF, J.Neurol.Sci., 1/1/2015
• Pregnancy outcomes following exposure to onabotulinumtoxinA  
  Brin MF, Kirby RS, Slavotinek A, Miller-Messana MA, Parker L, Yushmanova I, Yang H, Pharmacoepidemiol.Drug Saf., 1/1/2015
• Botulinum toxin type A products are not interchangeable: A review of the evidence  
  Brin MF, James C, Maltman J, Biologics Targ Therap, 1/1/2014
• Cervical dystonia and pain: Characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy)  
  Charles PD, Adler CH, Stacy M, Comella C, Jankovic J, Adams A, Schwartz M, Brin MF, J Neurol, 1/1/2014
• Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine  
  Diener H-C, Dodick DW, Turkel CC, Demos G, Degryse RE, Earl NL, Brin MF, Eur J Neurology, 1/1/2014
• Fusion of Golgi-derived vesicles mediated by SNAP-25 is essential for sympathetic neuron outgrowth but relatively insensitive to botulinum neurotoxins in vitro  
  Lawrence GW, Wang J, Brin MF, Aoki KR, Wheeler L, Dolly JO, FEBS J, 1/1/2014
• Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia  
  Marsh WA, Monroe DM, Brin MF, Gallagher CJ, BMC Neurology, 1/1/2014
• Development of onabotulinumtoxinA for chronic migraine  
  Whitcup SM, Turkel CC, DeGryse RE, Brin MF, Ann NY Acad Sci, 1/1/2014
• Surgical management of airway dysfunction in parkinson's disease compared with parkinson-plus syndromes  
  Sinclair CF, Gurey LE, Brin MF, Stewart C, Blitzer A, Ann Otol Rhinol Laryngol, 1/1/2013
• Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia  
  Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF, Clin Neuropharm, 1/1/2012
• Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity  
  Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, Brin MF, Jenkins B, Haag-Molkenteller C, J Urol, 1/1/2012
• Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled...  
  Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C, Eur Urol, 1/1/2011
• Novel mutation in the TOR1A (DYT1) gen in atypical, early onset dystonia and polymorphisms in dystonia and early onset parkinsonism  
  Leung JC, Klein C, Friedman J, Viergge P, Jacobs H, Doheny D, Kamm C, De LD, Pramstaller PP, Penney JB, Eisengart M, Jankovic J, Gasser T, Bressman SB, Corey DP, Krame..., Neurology, 1/1/2011
• OnabotulinumtoxinA for treatment of chronic migraine + Author's Reply  
  Markert RJ, Solomon GD, Dodick DW, Turkel CC, Degryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, Headache, 1/1/2011
• Dose response with onabotulinumtoxinA for post-stroke spasticity: a pooled data analysis  
  Yablon SA, Brin MF, VanDenburgh AM, Zhou J, Garabedian-Ruffalo SM, Abu-Shakra S, Beddingfield FC, III, Mov Disord, 1/1/2011
• Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE)  
  Jankovic J, Adler CH, Charles PD, Comella C, Stacy M, Schwartz M, Sutch SM, Brin MF, Papapetropoulos S, BMC Neurol, 1/1/2011
• Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX�) across multiple indications  
  Naumann M, Carruthers A, Carruthers J, Aurora SK, Zafonte R, Abu-Shakra S, Boodhoo T, Miller-Messana MA, Demos G, James L, Beddingfield F, Vandenburgh A, Chapman MA, B..., Mov Disord, 1/1/2010
• Genetic evidence for an association of the TOR1A locus with segmental/focal dystonia  
  Sharma N, Franco RA, Jr., Kuster JK, Mitchell AA, Fuchs T, Saunders-Pullman R, Raymond D, Brin MF, Blitzer A, Bressman SB, Ozelius LJ, Mov Disord, 1/1/2010
• Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in...  
  Brin MF, Boodhoo TI, Pogoda JM, James LM, Demos G, Terashima Y, Gu J, Eadie N, Bowen BL, J Am Acad Dermatol, 1/1/2009
• Differences in botulinum toxins: time to end the confusion  
  Brin MF, Tan K, Gallagher C, J.Cosmet.Laser Ther., 1/1/2009
• Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay  
  Brin MF, Comella CL, Jankovic J, Lai F, Naumann M, Mov Disord, 1/1/2008
• Phenotypic spectrum and sex effects in eleven myoclonus-dystonia families with epsilon-sarcoglycan mutations  
  Raymond D, Saunders-Pullman R, de Carvalho AP, Schule B, Kock N, Friedman J, Harris J, Ford B, Frucht S, Heiman GA, Jennings D, Doheny D, Brin MF, de Leon BD, Multhaup..., Mov Disord, 1/1/2008
• Join now to see all

Books/Book Chapters

• Botulinum Toxin (Procedures in Cosmetic Dermatology Series) 
  Chapter: History of onabotulinumtoxinA therapeutic 
  Page 6 - 12Brin MF, Blitzer AEditors: Carruthers A, Carruthers J.Elsevier, New York, NYEdition 3rd,2013
• The differential diagnosis of chorea 
  Chapter: Forward 
  Brin MFEditors: Walker RH.2011
• Neurologic Disorders of the Larynx 
  Chapter: Movement disorders of the larynx 
  Page 160 - 195Brin MF, Blitzer A, Velickovic MEditors: Blitzer A, Brin MF, Ramig LO.Thieme, New York, NYEdition 2nd,2009
• Neurologic Disorders of the Larynx 
  Blitzer A, Brin MF, Ramig LOThieme, New York, NYEdition 2nd,2009
• Dystonia: Etiology, Clinical Features, and Treatment 
  Chapter: Other uses of botulinum toxin type A therapy 
  Page 213 - 228Brin MF, Jankovic JEditors: Brin MF, Comella C, Jankovic J.Lippincott Williams and Wilkins, Philadelphia, PA2004
• Dystonia: Etiology, Clinical Features, and Treatment 
  Chapter: Pharmacology of botulinum toxin therapy 
  Page 93 - 112Brin MF, Aoki KR, Dressler DEditors: Brin MF, Comella C, Jankovic J.Lippincott Williams and Wilkins, Philadelphia, PA2004
• Dystonia: Etiology, Clinical Features, and Treatment 
  Chapter: Pathophysiology of dystonia 
  Page 5 - 10Brin MF, Comella CEditors: Brin MF, Comella C, Jankovic J.Lippincott Williams and Wilkins, Philadelphia, PA2004
• Dystonia: Etiology, Clinical Features, and Treatment 
  Editors: Brin MF, Comella C, and Jankovic J.Lippincott Williams and Wilkins, Philadelphia, PA2004
• Management of Parkinson's Disease: An Evidence-Based Review 
  Editors: Goetz CG, Koller WC, Poewe W, Rascol O, Sampaio C, Brin MF, Lees AJ, LeWitt P, Lozano A, Mizuno Y, Nutt J, Oertel W, Olanow CW, Tolosa E, Brefel-Courbon C, Eichhorn T, Ferreira J, Katzenschlager R, Luginger E, Pastor P, Seppi K, Spieker S.Wiley, Hoboken, NJ2002
• Neuroacanthocytosis syndromes: New Perspectives for the Study of Basal Ganglia Degeneration 
  Chapter: Autosomal dominant chorea-acanthocytosis: Report of a family and neuropathology 
  Walker RH, Morgello S, Davidoff-Feldman B, Melnick A, Walsh MJ, Shashidharan P, Brin MFEditors: Danek A.Springer-Verlag2002
• Scientific and Therapeutic Aspects of Botulinum Toxin 
  Chapter: Effects of botulinum toxin at the neuromuscular junction 
  Hallett MEditors: Brin MF, Hallett M, Jankovic J.Lippincott Williams and Wilkins, New York, NY2002
• Scientific and Therapeutic Aspects of Botulinum Toxin 
  Chapter: Botulinum toxin type A for pain and headache 
  Editors: Brin MF, Hallett M, Jankovic J.Lippincott Williams and Wilkins, New York, NY2002
• Scientific and Therapeutic Aspects of Botulinum Toxin 
  Editors: Brin MF, Hallett M, and Jankovic, J.Lippincott Williams and Wilkins, New York, NY2002
• Surgery for Movement Disorders 
  Chapter: Deep brain stimulation in the treatment of dystonia 
  Page 307 - 315Brin MF, Germano I, Danisi F, Weisz D, Olanow CWLippincott Williams and Wilkins, Philadelphia, PA2001
• Diagnosis and treatment of Parkinson�s disease: A handbook for primary care physicians 
  Comella CL, Brin MF, Brownlee HJRush Presbyterian Medical Center, Chicago, IL2000
• Parkinson's Disease and Quality of Life 
  Chapter: Physician and patients in managing Parkinson's disease 
  Page 11 - 13Brin MFEditors: Cote L, Sprinzeles LL, Elliott R, Kutscher AH.Haworth Press, Binghamton, NY2000
• Management of Facial Lines and Wrinkles 
  Chapter: Botulinum toxin therapy: Basic science and overview of other therapeutic applications 
  Page 279 - 302Brin MFEditors: Blitzer A, Binder WJ, Boyd JB, Carruthers A.Lippincott Williams & Wilkins, New York, NY2000
• Management of Facial Lines and Wrinkles 
  Chapter: Botulinum toxin injections for facial lines and wrinkles: Technique 
  Page 303 - 313Blitzer A, Binder WJ, Brin MFEditors: Blitzer A, Binder WJ, Boyd BJ, Carruthers A.Lippincott Williams & Wilkins, New York, NY2000
• Textbook of Motor Disorders 
  Chapter: Evaluation and management of swallowing and voice disorders 
  Page 477 - 492Stewart CF, Blitzer A, Brin MFEditors: Younger DS.Lippincott Williams & Wilkins, Philadelphia, PA1999
• Textbook of Motor Disorders 
  Chapter: Botulinum toxin for motor disorders 
  Page 515 - 522Brin MFEditors: Younger DS.Lippincott Williams & Wilkins, Philadelphia, PA1999
• Office-Based Surgery of the Head and Neck 
  Chapter: Management of facial wrinkles with botulinum toxin injections 
  Page 251 - 254Blitzer A, Binder WJ, Brin MFEditors: Krespi YP.Lippincott-Raven, New York, NY1998
• Neurosurgical Treatment of Movement Disorders 
  Chapter: Pharmacological treatment of movement disorders 
  Page 83 - 104Brin MFEditors: Germano I.Amer Assoc Neurol Surgeons, Lebanon1998
• Parkinson's Disease and Movement Disorders 
  Chapter: Treatment of dystonia 
  Page 553 - 578Brin MFEditors: Jankovic J, Tolosa E.Williams & Wilkins, New York, NY1997
• Spasticity: Etiology, Evaluation, Management, and the Role of Botulinum Toxin Type A: A training syllabus developed by the Spasticity Study Group 
  Editors: Brin MF.1997
• Introduction to Organic and Neurogenic Disorders of Communication: Current Scope of Practice. Needham Heights 
  Chapter: Spasmodic dysphonia 
  Page 301 - 318Stewart CS, Brin MF, Blitzer AEditors: Ferrand CT, Bloom RL.Allyn & Bacon, Needham Heights, MA1997
• Join now to see all

Abstracts/Posters

• Effects of onabotulinumtoxinA treatment on the chronic migraine comorbidities of depression, anxiety, sleep and fatigue
  Brin MF, Manack Adams A, Interagency Botulism Research Coordinating Committee - 54th Annual Meeting, Burlingame, CA, 1/22/2017
• The psychological impact of horizontal frontalis lines, glabellar lines, and lateral canthal lines: qualitative, patient-centered studies
  Brin MF, Dayan S, Yoelin SG, De Boulle K, Garcia J, Ferrusi IL, Interagency Botulism Research Coordinating Committee - 54th Annual Meeting, Burlingame, CA, 1/22/2017
• Botulinum neurotoxin type A�cleaved SNAP25 is confined to primary motor neurons and expressed on the plasma membrane following intramuscular toxin injection
  Broide R, Cai B, Francis J, Brin MF, Society for Neuroscience - 46th Annual Meeting; International Neurotoxin Association - 3rd Conference (TOXINS), San Diego, CA, 2016; Madrid, Spain, 2017, 1/18/2017
• Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a statistical meta-analysis of pooled data from global registration studies of treatmen...
  Carruthers J, Brin MF, De Boulle K, Liew S, Carruthers A, Rivkin A, Wu Y, Yushmanova I, Boodhoo TI, Zhuang K, Gallagher CJ, Lee E, Multiple presentations, Multiple locations, 2016, 2017, 1/6/2017
• Clinical relevance of treatment with onabotulinumtoxinA in patients with cervical dystonia: results from the CD PROBE Study
  Dashtipour K, Mari Z, Jankovic J, Adler CH, Schwartz M, Brin MF, International Neurotoxin Association - 3rd Conference (TOXINS); Movement Disorder Society - 21st International Congress of Parkinson's Disease and Movement Disorders; American Academy of Neurology - 69th Annual Meeting, 1/1/2017
• Safety of onabotulinumtoxinA treatment with concomitant antithrombotic therapy in patients with post-stroke spasticity: a pooled analysis of randomized, double-blind s...
  Dimitrova R, James L, Liu C, Orejudos A, Yushmanova I, Brin MF, International Neurotoxin Association - 3rd Conference (TOXINS); American Academy of Neurology - 69th Annual Meeting, 1/1/2017
• Long-term safety and tolerability of onabotulinumtoxinA treatment in chronic migraine patients: COMPEL analysis by treatment cycle
  Winner P, Blumenfeld A, Eross E, Orejudos A, Manack Adams A, Brin MF, International Headache Society - 18th International Headache Congress, 1/1/2017
• Emerging safety assessment for onabotulinumtoxinA across currently approved indications in over 9000 patients
  Brin MF, Yushmanova I, Interagency Botulism Research Coordinating Committee - 53rd Annual Meeting, 1/1/2016
• Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors� responses to stimulation of TRPV1 and TRPA1 channels: Are we getting...
  Brin MF, Zhang XC, Strassman A, Novack V, Burstein R, Interagency Botulism Research Coordinating Committee - 53rd Annual Meeting, 1/1/2016
• Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A (BoNT-A): Therapeutic implications to migraine and other pains
  Burstein R, Zhang XC, Levy D, Aoki KR, Brin MF, Neurology, 1/1/2014
• Treatment patterns and patient disposition in the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE)
  Charles D, Jankovic J, Adler CH, Comella C, Stacy M, Schwartz M, Manack A, Brin MF, Mov Disord, 1/1/2014
• Evaluation of pain relief in the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE)
  Charles D, Patel A, Schwartz M, Manack A, Brin MF, Mov Disord, 1/1/2014
• Cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD probe): Treatment patterns and subject disposition
  Charles P, Jankovic J, Comella C, Stacy M, Schwartz M, Manack A, Brin MF, Neurology, 1/1/2014
• Treatment outcomes in cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD probe)
  Jankovic J, Adler C, Charles P, Comella C, Stacy M, Schwartz M, Manack A, Brin MF, Neurology, 1/1/2014
• Effectiveness and safety in the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE)
  Jankovic J, Adler CH, Charles D, Comella C, Stacy M, Schwartz M, Manack A, Brin MF, Mov Disord, 1/1/2014
• Effectiveness and safety in the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE)
  Manack A, Jankovic J, Adler CH, Charles D, Stacy M, Schwartz M, Brin MF, PM&R, 1/1/2014
• Improvement in quality of life after onabotulinumtoxinA treatment in the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE)
  Mari Z, Manack A, Schwartz M, Brin MF, Comella C, Mov Disord, 1/1/2014
• Evaluation of pain relief in the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE)
  Patel A, Jankovic J, Schwartz M, Brin MF, Charles D, PM&R, 1/1/2014
• Use of electromyography for botulinum toxin treatment of cervical dystonia: A subanalysis of the cervical dystonia patient registry for the observation of onabotulinum...
  Comella C, Jankovic J, Adler C, Charles D, Stacy M, Schwartz M, Brin M, Botulinum J, 1/1/2013
• Phase 3 efficacy and safety study of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity
  Dmochowski R, Ginsberg D, Ethans K, Brin MF, Lam W, Haag-Molkenteller C, Toxicon, 1/1/2013
• OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phase of the PREEMPT clinical program
  Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, Toxicon, 1/1/2013
• Cervical Dystonia Patient Registry for Observation of onaBotulinumtoxinA Efficacy (CD PROBE): Interim results of physician- and patient-reported outcomes
  Papapetropoulos S, Jankovic J, Stacy M, Charles PD, Adler C, Brin MF, CD PROBE Study Group, Toxicon, 1/1/2013
• Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE): Baseline demographic and clinical characteristics
  Jankovic J, Charles P, Adler C, Comella C, Stacy M, Schwartz M, Brin MF, Neurology, 1/1/2013
• Pregnancy outcomes following onabotulinumtoxinA exposure
  Yang H, Li JQ, Brin MF, Neurotherapeutics, 1/1/2013
• Cervical Dystonia Patient Registry for Observation of onaBotulinumtoxinA Efficacy (CD PROBE): Baseline demographic and clinical characteristics
  Jankovic J, Charles D, Adler C, Comella C, Stacy M, Schwartz M, Brin MF, Mov Disord, 1/1/2013
• Join now to see all

Other

• The Role of Chemodenervation in Spasticity Management (Videotape) 
  Brin MF, O'Brien CF, Gormley ME, McGuire J, Blazer J, WE MOVE
  www.wemove.org
  New York, NY - 1/1/2000
• New Advances in the Management of Spasticity and Muscle Overactivity (CD Rom) 
  Esquenazi A, Mayer N, Professional Postgraduate Services
  Knoxville, TN - 1/1/2000
• Advances in dystonia: Classification, genetics and therapeutics 
  Brin MF, Neuroscience Year: Supplement to the Encyclopedia of Neuroscience
  1/1/1999
• Botulinum Toxin Treatment of Cervical Dystonia (Videotape) 
  Jankovic J, Brin MF, Comella CL, Blazer J, Churchill Livingstone
  New York, NY - 1/1/1994
• Dystonia 
  WE MOVE
  www.wemove.org
• Parkinson�s disease 
  WE MOVE
  www.wemove.org
• Tics/Tourettes 
  WE MOVE
  www.wemove.org
• Myoclonus 
  WE MOVE
  www.wemove.org
• Rremor 
  WE MOVE
  www.wemove.org
• Spasticity 
  WE MOVE
  www.wemove.org
• Join now to see all